Overview
Galectin Therapeutics Inc., based in the United States, is a biotechnology firm focused on the development of therapies that target galectin proteins to treat fibrotic and other diseases. The company's lead project involves a proprietary compound, GR-MD-02, which is designed to inhibit galectin-3, a protein implicated in fibrosis (tissue scarring) and cancer. Galectin Therapeutics Inc. is actively involved in various clinical trials, primarily focusing on treatments for conditions such as non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis. Moreover, the company is exploring the therapeutic potential of its galectin inhibitors in other diseases characterized by severe fibrosis. In its endeavors, Galectin Therapeutics works towards developing novel therapeutic interventions that could provide significant clinical benefits in areas currently lacking effective treatments.
AI+ Ask Fintel’s AI assistant about Galectin Therapeutics Inc..
Thinking about good questions…
Basic Stats
The share price of Galectin Therapeutics Inc. as of 5 September 2025 is 3,96 € / share. This is an increase of 10.00% from the prior week. The market cap (or net worth) of Galectin Therapeutics Inc. as of 5 September 2025 is 252,40 € MM.
The Factor Analysis chart (below right) shows a view of Galectin Therapeutics Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 252.40 MM |
| EV | |
| Shares Out. | 64.06 MM |
| Earnings Date | |
| EPS (TTM) | -0.63 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 82.41 % |
| Volatility (1 yr) | 1.24 |
| Beta | 0.67 |
| Sharpe Ratio (1 yr) | 0.63 |
| Sortino Ratio (1 yr) | 1.08 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -1.46 |
| ROE | |
| ROIC | -0.39 |
| CROIC | -0.12 |
| OCROIC | -0.35 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 48.91 /100 |
| Profitability | 7.67 /100 |
| Quality Score | 17.68 /100 |
| Value Score | |
| Momentum Score | 97.18 /100 |
| Stability (Low Vol) Score | 10.04 /100 |
| Analyst Sentiment | |
| Fund Sentiment | 63.11 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 2.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Galectin Therapeutics Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| No data available. | ||||
